查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1856985

全球mRNA疫苗和療法市場：預測至2032年－按產品、結構、遞送系統、給藥途徑、應用、最終用戶和地區進行分析

mRNA Vaccines and Therapeutics Market Forecasts to 2032 - Global Analysis By Product (mRNA Vaccines, mRNA Therapeutics and mRNA-Based Diagnostics), Construct Type, Delivery System, Route of Administration, Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，全球 mRNA 疫苗和治療市場預計到 2025 年將達到 266.4 億美元，到 2032 年將達到 780.8 億美元，年複合成長率為 16.6%。

mRNA疫苗和療法是創新的生物醫學干預手段，它利用傳訊RNA（mRNA）分子來指導細胞產生特定的蛋白質（通常是抗原），從而觸發免疫反應。與通常依賴去活化病原體或蛋白質次單元的傳統疫苗不同，基於mRNA的方法利用人體自身的細胞機制來產生目標蛋白，安全有效地刺激免疫反應。這些平台具有設計快速、可擴展生產以及適應新出現的感染疾病優勢。除了疫苗之外，mRNA療法還具有治療遺傳性疾病、癌症和其他疾病的潛在應用價值，它能夠實現患者細胞內精確的蛋白質表現和基因調控。

慢性病增多

mRNA平台能夠快速開發標靶治療，進而調節免疫反應和蛋白質表現。癌症、糖尿病和呼吸系統疾病的日益普遍，推動了對個人化和預防性療法的投資。製藥公司和生技新興企業正在拓展其mRNA研發管線，以滿足尚未滿足的臨床需求並縮短治療週期。與基因組分析和生物標記發現相結合，可提高治療的精準性和療效。這些發展趨勢正在推動該平台在慢性病管理和免疫療法領域的應用。

穩定性和儲存問題

mRNA分子本身不穩定，需要低溫運輸物流來維持其效力和安全性。超低溫儲存和運輸基礎設施增加了整個分銷鏈的成本和複雜性。由於基礎設施不足和對溫度的敏感性，在農村和資源匱乏地區推廣mRNA疫苗面臨許多挑戰。儘管改良的配方和冷凍乾燥技術正在研發中，但其商業性應用仍受到限制。這些限制因素阻礙了mRNA疫苗在供應鏈中的公平取得和營運效率。

mRNA技術的進步

自擴增mRNA、環狀RNA和耐熱製劑正在提升臨床應用中的療效、持久性和遞送效率。相關平台支援快速抗原設計、可擴展生產以及針對新興病原體和個人化醫療的模組化客製化。對脂質奈米顆粒載體和肌肉注射系統的投入提高了生物有效性和免疫活化能力。監管機構正在簡化基於mRNA的候選藥物在應對疫情和腫瘤治療領域的核准途徑。這些趨勢正在推動下一代mRNA平台和治療管線的發展。

大眾認知與疫苗猶豫

錯誤訊息、安全疑慮以及疫苗宣傳活動的政治化降低了公眾的信任度和接種率。長期數據和上市後監測缺乏透明度，使得風險溝通和相關人員參與變得更加複雜。不同文化和地區在醫療素養和信任度方面的差異，進一步限制了疫苗在全球市場的普及。製藥公司和公共衛生機構必須加強對教育、透明度和社區宣傳的投入，以減少抵制情緒。這些挑戰持續限制著mRNA疫苗計畫的市場滲透率和公共衛生影響。

新冠疫情的影響：

新冠疫情加速了mRNA平台的檢驗和商業化進程，輝瑞-BioNTech和Moderna的疫苗展現了高效能和快速擴充性的能力。緊急使用核准和全球推廣應用證明了mRNA技術在危機應變中的速度和適應性。為支持大規模免疫接種和變異株靶向，研發、生產和低溫運輸基礎設施的投資激增。消費者和臨床領域對mRNA科學及其潛在應用的認知度也隨之提升。後疫情時代的策略已將mRNA視為疫苗創新、疫情防範和治療藥物研發的重要支柱。

預計在預測期內，脂質奈米顆粒（LNP）遞送系統細分市場將達到最大。

預計在預測期內，脂質奈米顆粒（LNP）遞送系統將佔據最大的市場佔有率，因為它在穩定mRNA有效載荷並將其轉運穿過細胞膜方面發揮關鍵作用。 LNP可保護mRNA免受分解，並促進抗原表達和免疫活化的細胞內遞送。該平台利用可電離脂質、聚乙二醇化脂質和膽固醇載體來最佳化藥物動力學和組織靶向性。疫苗和治療藥物研發管線對可擴展、生物相容且經過臨床檢驗的遞送系統的需求正在不斷成長。

預計在預測期內，自擴增mRNA細分市場將達到最高的複合年成長率。

由於其能夠在細胞內複製並以較低劑量產生更高蛋白產量，因此預計自擴增mRNA片段在預測期內將呈現最高的成長速度。 saRNA平台可降低生產成本，並提高預防和治療應用中的免疫抗原性。與耐熱製劑和無針給藥系統的結合，拓展了其在應對疫情和全球疫苗接種方面的應用範圍。學術界和商業性研發領域對癌症、呼吸系統疾病和熱帶疾病計畫的投入正在增加。這些趨勢正在加速自擴增mRNA創新和臨床應用的發展。

比最大的地區

由於北美擁有先進的生物技術生態系統、完善的監管機制和商業基礎設施，預計在預測期內將佔據最大的市場佔有率。美國和加拿大的公司在疫苗和治療藥物的mRNA研發、生產和臨床試驗方面佔據主導地位。對低溫運輸物流、基因組醫學和官民合作關係的投資支持了平台的擴充性和部署。大型製藥公司、學術機構和監管機構的存在推動了創新和標準化進程。

複合年成長率最高的地區：

預計亞太地區在預測期內將呈現最高的複合年成長率，這主要得益於醫療現代化、感染疾病負擔以及生物技術投資在該地區各國經濟中的融合。中國、印度、韓國和新加坡等國家正在擴大mRNA平台在公共衛生計畫、腫瘤試驗和出口導向製造領域的應用規模。政府支持的舉措正在幫助疫苗和治療藥物研發管線的基礎建設、監管改革和新興企業。本土企業正在推出適應當地氣候和人口需求的配方和給藥系統。這些趨勢正在推動亞太地區mRNA創新和臨床應用的成長。

免費客製化服務

訂閱本報告的用戶可從以下免費自訂選項中選擇一項：

  • 公司簡介
    • 對最多三家其他公司進行全面分析
    • 對主要企業進行SWOT分析（最多3家公司）
  • 區域分類
    • 根據客戶興趣對主要國家進行市場估算、預測和複合年成長率分析（註：基於可行性檢查）
  • 競爭基準化分析
    • 基於產品系列、地域覆蓋和策略聯盟對主要企業基準化分析

目錄

第1章執行摘要

第2章 引言

  • 概述
  • 相關利益者
  • 分析範圍
  • 分析方法
    • 資料探勘
    • 數據分析
    • 數據檢驗
    • 分析方法
  • 分析材料
    • 原始研究資料
    • 二手研究資訊來源
    • 先決條件

第3章 市場趨勢分析

  • 促進要素
  • 抑制因素
  • 市場機遇
  • 威脅
  • 產品分析
  • 應用分析
  • 終端用戶分析
  • 新興市場
  • 新冠疫情的感染疾病

第4章 波特五力分析

  • 供應商的議價能力
  • 買方議價能力
  • 替代產品的威脅
  • 新參與企業的威脅
  • 公司間的競爭

5. 全球mRNA疫苗和療法市場（按產品分類）

  • mRNA疫苗
  • mRNA療法
  • 基於mRNA的診斷

6. 全球mRNA疫苗和療法市場（按結構類型分類）

  • 常規非複製型mRNA
  • 自擴增mRNA
  • 環狀mRNA
  • 修飾的mRNA

7. 全球mRNA疫苗和療法市場（依遞送系統分類）

  • 脂質奈米顆粒（LNPs）
  • 基於聚合物的奈米載體
  • 陽離子奈米乳液
  • 基於胜肽的載體
  • 病毒載體

8. 全球mRNA疫苗和療法市場（依給藥途徑分類）

  • 肌肉內注射
  • 靜脈
  • 皮下
  • 皮內注射

9. 全球mRNA疫苗和療法市場（按應用分類）

  • 感染疾病
  • 瘤
  • 自體免疫疾病
  • 遺傳性疾病
  • 蛋白質替代療法
  • 其他用途

第10章：全球mRNA疫苗和療法市場（按最終用戶分類）

  • 醫院和診所
  • 研究所
  • 生物製藥公司
  • CRO/CDMO
  • 政府和公共衛生機構
  • 其他最終用戶

第11章 全球mRNA疫苗和療法市場（按地區分類）

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東和非洲地區

第12章：主要趨勢

  • 合約、商業夥伴關係和合資企業
  • 企業合併（M&A）
  • 新產品發布
  • 業務拓展
  • 其他關鍵策略

第13章：公司簡介

  • Moderna, Inc.
  • BioNTech SE
  • CureVac NV
  • Arcturus Therapeutics
  • Pfizer Inc.
  • Sanofi SA
  • GlaxoSmithKline plc（GSK）
  • AstraZeneca plc
  • Daiichi Sankyo Company, Limited
  • Gennova Biopharmaceuticals Ltd.
  • Translate Bio
  • eTheRNA Immunotherapies
  • Strand Therapeutics
  • Omega Therapeutics
  • Chimeron Bio
Product Code: SMRC31850

According to Stratistics MRC, the Global MRNA Vaccines and Therapeutics Market is accounted for $26.64 billion in 2025 and is expected to reach $78.08 billion by 2032 growing at a CAGR of 16.6% during the forecast period. mRNA vaccines and therapeutics are innovative biomedical interventions that use messenger RNA (mRNA) molecules to instruct cells to produce specific proteins, typically antigens, that trigger an immune response. Unlike traditional vaccines, which often rely on inactivated pathogens or protein subunits, mRNA-based approaches harness the body's own cellular machinery to generate the target protein, stimulating immunity safely and efficiently. These platforms offer rapid design, scalable manufacturing, and adaptability against emerging infectious diseases. Beyond vaccines, mRNA therapeutics hold potential for treating genetic disorders, cancers, and other conditions by enabling precise protein expression or gene modulation within the patient's cells.

Market Dynamics:

Driver:

Increasing prevalence of chronic diseases

mRNA platforms enable rapid development of targeted treatments that modulate immune response and protein expression. Rising incidence of cancer, diabetes, and respiratory conditions is driving investment in personalized and preventive therapies. Pharmaceutical firms and biotech startups are scaling mRNA pipelines to address unmet clinical needs and reduce treatment latency. Integration with genomic profiling and biomarker discovery enhances therapeutic precision and efficacy. These dynamics are propelling platform expansion across chronic disease management and immunotherapy.

Restraint:

Stability and storage issues

mRNA molecules are inherently unstable and require cold-chain logistics to maintain potency and safety. Ultra-low temperature storage and transport infrastructure increases cost and complexity across distribution networks. Rural and resource-constrained regions face challenges in deploying mRNA vaccines due to infrastructure gaps and temperature sensitivity. Formulation improvements and lyophilization techniques are under development but remain commercially limited. These constraints continue to hinder equitable access and operational efficiency across mRNA supply chains.

Opportunity:

Advancements in mRNA Technology

Self-amplifying mRNA, circular RNA, and thermostable formulations are improving efficacy, durability, and delivery across clinical applications. Platforms support rapid antigen design, scalable manufacturing, and modular customization for emerging pathogens and personalized medicine. Investment in lipid nanoparticle carriers and intramuscular delivery systems enhances bioavailability and immune activation. Regulatory bodies are streamlining approval pathways for mRNA-based candidates across pandemic preparedness and oncology. These trends are fostering growth across next-generation mRNA platforms and therapeutic pipelines.

Threat:

Public perception and vaccine hesitancy

Misinformation, safety concerns, and politicization of vaccine campaigns degrade public confidence and compliance. Lack of long-term data and post-market surveillance transparency complicates risk communication and stakeholder engagement. Cultural and regional differences in healthcare literacy and trust further constrain adoption across global markets. Pharmaceutical firms and public health agencies must invest in education, transparency, and community outreach to mitigate resistance. These challenges continue to limit market penetration and public health impact across mRNA programs.

Covid-19 Impact:

The pandemic accelerated mRNA platform validation and commercialization as Pfizer-BioNTech and Moderna vaccines demonstrated high efficacy and rapid scalability. Emergency use authorizations and global deployment showcased the speed and adaptability of mRNA technologies in crisis response. Investment surged across R&D, manufacturing, and cold-chain infrastructure to support mass immunization and variant targeting. Public awareness of mRNA science and its potential applications increased across consumer and clinical segments. Post-pandemic strategies now include mRNA as a core pillar of vaccine innovation, pandemic preparedness, and therapeutic development.

The lipid nanoparticle (LNP) delivery systems segment is expected to be the largest during the forecast period

The lipid nanoparticle (LNP) delivery systems segment is expected to account for the largest market share during the forecast period due to their critical role in stabilizing and transporting mRNA payloads across cellular membranes. LNPs protect mRNA from degradation and facilitate intracellular delivery for antigen expression and immune activation. Platforms use ionizable lipids, PEGylated lipids, and cholesterol-based carriers to optimize pharmacokinetics and tissue targeting. Demand for scalable, biocompatible, and clinically validated delivery systems is rising across vaccine and therapeutic pipelines.

The self-amplifying mRNA segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the self-amplifying mRNA segment is predicted to witness the highest growth rate due to its ability to replicate intracellularly and produce higher protein yields with lower doses. saRNA platforms reduce manufacturing cost and improve immunogenicity across prophylactic and therapeutic applications. Integration with thermostable formulations and needle-free delivery systems expands use cases across pandemic response and global immunization. Investment in oncology, respiratory, and tropical disease programs is rising across academic and commercial R&D. These dynamics are accelerating growth across self-amplifying mRNA innovation and clinical translation.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share due to its advanced biotech ecosystem, regulatory engagement, and commercial infrastructure. U.S. and Canadian firms dominate mRNA R&D, manufacturing, and clinical trials across vaccines and therapeutics. Investment in cold-chain logistics, genomic medicine, and public-private partnerships supports platform scalability and deployment. Presence of leading pharmaceutical companies, academic institutions, and regulatory bodies drives innovation and standardization.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR as healthcare modernization, infectious disease burden, and biotech investment converge across regional economies. Countries like China, India, South Korea, and Singapore scale mRNA platforms across public health programs, oncology trials, and export-oriented manufacturing. Government-backed initiatives support infrastructure development, regulatory reform, and startup incubation across vaccine and therapeutic pipelines. Local firms launch regionally adapted formulations and delivery systems tailored to climate and population needs. These trends are accelerating regional growth across mRNA innovation and clinical deployment.

Key players in the market

Some of the key players in MRNA Vaccines and Therapeutics Market include Moderna, Inc., BioNTech SE, CureVac N.V., Arcturus Therapeutics, Pfizer Inc., Sanofi S.A., GlaxoSmithKline plc (GSK), AstraZeneca plc, Daiichi Sankyo Company, Limited, Gennova Biopharmaceuticals Ltd., Translate Bio, eTheRNA Immunotherapies, Strand Therapeutics, Omega Therapeutics and Chimeron Bio.

Key Developments:

In March 2025, Moderna expanded its partnership with CARsgen Therapeutics to co-develop mRNA-based CAR-T therapies targeting solid tumors. The collaboration integrates Moderna's mRNA delivery expertise with CARsgen's tumor-specific antigen platforms, aiming to overcome immunosuppressive microenvironments in cancers like glioblastoma and pancreatic adenocarcinoma.

In January 2025, BioNTech announced the advancement of BNT327/PM8002, a next-generation mRNA-based immuno-oncology backbone. The candidate supports pan-tumor treatment approaches and is being positioned for combination with antibody-drug conjugates (ADCs). The launch includes global clinical trials targeting small cell and non-small cell lung cancer, with registrational potential.

Products Covered:

  • mRNA Vaccines
  • mRNA Therapeutics
  • mRNA-Based Diagnostics

Construct Types Covered:

  • Conventional Non-Replicating mRNA
  • Self-Amplifying mRNA
  • Circular mRNA
  • Modified mRNA

Delivery Systems Covered:

  • Lipid Nanoparticles (LNPs)
  • Polymer-Based Nanocarriers
  • Cationic Nano-Emulsions
  • Peptide-Based Carriers
  • Viral Vectors

Route of Administrations Covered:

  • Intramuscular
  • Intravenous
  • Subcutaneous
  • Intradermal

Applications Covered:

  • Infectious Diseases
  • Oncology
  • Autoimmune Disorders
  • Genetic Disorders
  • Protein Replacement Therapy
  • Other Applications

End Users Covered:

  • Hospitals & Clinics
  • Research Institutions
  • Biopharma Companies
  • CROs & CDMOs
  • Government & Public Health Agencies
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 Application Analysis
  • 3.8 End User Analysis
  • 3.9 Emerging Markets
  • 3.10 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global mRNA Vaccines and Therapeutics Market, By Product

  • 5.1 Introduction
  • 5.2 mRNA Vaccines
  • 5.3 mRNA Therapeutics
  • 5.4 mRNA-Based Diagnostics

6 Global mRNA Vaccines and Therapeutics Market, By Construct Type

  • 6.1 Introduction
  • 6.2 Conventional Non-Replicating mRNA
  • 6.3 Self-Amplifying mRNA
  • 6.4 Circular mRNA
  • 6.5 Modified mRNA

7 Global mRNA Vaccines and Therapeutics Market, By Delivery System

  • 7.1 Introduction
  • 7.2 Lipid Nanoparticles (LNPs)
  • 7.3 Polymer-Based Nanocarriers
  • 7.4 Cationic Nano-Emulsions
  • 7.5 Peptide-Based Carriers
  • 7.6 Viral Vectors

8 Global mRNA Vaccines and Therapeutics Market, By Route of Administration

  • 8.1 Introduction
  • 8.2 Intramuscular
  • 8.3 Intravenous
  • 8.4 Subcutaneous
  • 8.5 Intradermal

9 Global mRNA Vaccines and Therapeutics Market, By Application

  • 9.1 Introduction
  • 9.2 Infectious Diseases
  • 9.3 Oncology
  • 9.4 Autoimmune Disorders
  • 9.5 Genetic Disorders
  • 9.6 Protein Replacement Therapy
  • 9.7 Other Applications

10 Global mRNA Vaccines and Therapeutics Market, By End User

  • 10.1 Introduction
  • 10.2 Hospitals & Clinics
  • 10.3 Research Institutions
  • 10.4 Biopharma Companies
  • 10.5 CROs & CDMOs
  • 10.6 Government & Public Health Agencies
  • 10.7 Other End Users

11 Global mRNA Vaccines and Therapeutics Market, By Geography

  • 11.1 Introduction
  • 11.2 North America
    • 11.2.1 US
    • 11.2.2 Canada
    • 11.2.3 Mexico
  • 11.3 Europe
    • 11.3.1 Germany
    • 11.3.2 UK
    • 11.3.3 Italy
    • 11.3.4 France
    • 11.3.5 Spain
    • 11.3.6 Rest of Europe
  • 11.4 Asia Pacific
    • 11.4.1 Japan
    • 11.4.2 China
    • 11.4.3 India
    • 11.4.4 Australia
    • 11.4.5 New Zealand
    • 11.4.6 South Korea
    • 11.4.7 Rest of Asia Pacific
  • 11.5 South America
    • 11.5.1 Argentina
    • 11.5.2 Brazil
    • 11.5.3 Chile
    • 11.5.4 Rest of South America
  • 11.6 Middle East & Africa
    • 11.6.1 Saudi Arabia
    • 11.6.2 UAE
    • 11.6.3 Qatar
    • 11.6.4 South Africa
    • 11.6.5 Rest of Middle East & Africa

12 Key Developments

  • 12.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 12.2 Acquisitions & Mergers
  • 12.3 New Product Launch
  • 12.4 Expansions
  • 12.5 Other Key Strategies

13 Company Profiling

  • 13.1 Moderna, Inc.
  • 13.2 BioNTech SE
  • 13.3 CureVac N.V.
  • 13.4 Arcturus Therapeutics
  • 13.5 Pfizer Inc.
  • 13.6 Sanofi S.A.
  • 13.7 GlaxoSmithKline plc (GSK)
  • 13.8 AstraZeneca plc
  • 13.9 Daiichi Sankyo Company, Limited
  • 13.10 Gennova Biopharmaceuticals Ltd.
  • 13.11 Translate Bio
  • 13.12 eTheRNA Immunotherapies
  • 13.13 Strand Therapeutics
  • 13.14 Omega Therapeutics
  • 13.15 Chimeron Bio

List of Tables

  • Table 1 Global mRNA Vaccines and Therapeutics Market Outlook, By Region (2024-2032) ($MN)
  • Table 2 Global mRNA Vaccines and Therapeutics Market Outlook, By Product (2024-2032) ($MN)
  • Table 3 Global mRNA Vaccines and Therapeutics Market Outlook, By mRNA Vaccines (2024-2032) ($MN)
  • Table 4 Global mRNA Vaccines and Therapeutics Market Outlook, By mRNA Therapeutics (2024-2032) ($MN)
  • Table 5 Global mRNA Vaccines and Therapeutics Market Outlook, By mRNA-Based Diagnostics (2024-2032) ($MN)
  • Table 6 Global mRNA Vaccines and Therapeutics Market Outlook, By Construct Type (2024-2032) ($MN)
  • Table 7 Global mRNA Vaccines and Therapeutics Market Outlook, By Conventional Non-Replicating mRNA (2024-2032) ($MN)
  • Table 8 Global mRNA Vaccines and Therapeutics Market Outlook, By Self-Amplifying mRNA (2024-2032) ($MN)
  • Table 9 Global mRNA Vaccines and Therapeutics Market Outlook, By Circular mRNA (2024-2032) ($MN)
  • Table 10 Global mRNA Vaccines and Therapeutics Market Outlook, By Modified mRNA (2024-2032) ($MN)
  • Table 11 Global mRNA Vaccines and Therapeutics Market Outlook, By Delivery System (2024-2032) ($MN)
  • Table 12 Global mRNA Vaccines and Therapeutics Market Outlook, By Lipid Nanoparticles (LNPs) (2024-2032) ($MN)
  • Table 13 Global mRNA Vaccines and Therapeutics Market Outlook, By Polymer-Based Nanocarriers (2024-2032) ($MN)
  • Table 14 Global mRNA Vaccines and Therapeutics Market Outlook, By Cationic Nano-Emulsions (2024-2032) ($MN)
  • Table 15 Global mRNA Vaccines and Therapeutics Market Outlook, By Peptide-Based Carriers (2024-2032) ($MN)
  • Table 16 Global mRNA Vaccines and Therapeutics Market Outlook, By Viral Vectors (2024-2032) ($MN)
  • Table 17 Global mRNA Vaccines and Therapeutics Market Outlook, By Route of Administration (2024-2032) ($MN)
  • Table 18 Global mRNA Vaccines and Therapeutics Market Outlook, By Intramuscular (2024-2032) ($MN)
  • Table 19 Global mRNA Vaccines and Therapeutics Market Outlook, By Intravenous (2024-2032) ($MN)
  • Table 20 Global mRNA Vaccines and Therapeutics Market Outlook, By Subcutaneous (2024-2032) ($MN)
  • Table 21 Global mRNA Vaccines and Therapeutics Market Outlook, By Intradermal (2024-2032) ($MN)
  • Table 22 Global mRNA Vaccines and Therapeutics Market Outlook, By Application (2024-2032) ($MN)
  • Table 23 Global mRNA Vaccines and Therapeutics Market Outlook, By Infectious Diseases (2024-2032) ($MN)
  • Table 24 Global mRNA Vaccines and Therapeutics Market Outlook, By Oncology (2024-2032) ($MN)
  • Table 25 Global mRNA Vaccines and Therapeutics Market Outlook, By Autoimmune Disorders (2024-2032) ($MN)
  • Table 26 Global mRNA Vaccines and Therapeutics Market Outlook, By Genetic Disorders (2024-2032) ($MN)
  • Table 27 Global mRNA Vaccines and Therapeutics Market Outlook, By Protein Replacement Therapy (2024-2032) ($MN)
  • Table 28 Global mRNA Vaccines and Therapeutics Market Outlook, By Other Applications (2024-2032) ($MN)
  • Table 29 Global mRNA Vaccines and Therapeutics Market Outlook, By End User (2024-2032) ($MN)
  • Table 30 Global mRNA Vaccines and Therapeutics Market Outlook, By Hospitals & Clinics (2024-2032) ($MN)
  • Table 31 Global mRNA Vaccines and Therapeutics Market Outlook, By Research Institutions (2024-2032) ($MN)
  • Table 32 Global mRNA Vaccines and Therapeutics Market Outlook, By Biopharma Companies (2024-2032) ($MN)
  • Table 33 Global mRNA Vaccines and Therapeutics Market Outlook, By CROs & CDMOs (2024-2032) ($MN)
  • Table 34 Global mRNA Vaccines and Therapeutics Market Outlook, By Government & Public Health Agencies (2024-2032) ($MN)
  • Table 35 Global mRNA Vaccines and Therapeutics Market Outlook, By Other End Users (2024-2032) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.